psa-1

ROS inducer 1 is a small molecule compound with bactericidal activity that inhibits the production of ROS in Xanthomonas axonopodis pv. citri (Xac), Xanthomonas oryzae pv. oryzae (Xoo) and Pseudomonas syringae pv. actinidiae (Psa). ROS inducer 1 induces ROS production in Xanthomonas cells and can be used to study bacterial infections in crops.

PSA1 141-150 acetate is used in the immunotherapy of cancer experiments that is a prostate specific antigen 1 peptide.

This Prostate Specific Antigen 1 peptide was used in the immunotherapy of cancer experiments.

Clazakizumab, a monoclonal antibody, demonstrates high affinity and specificity towards the interleukin-6 (IL-6) cytokine, potentially inhibiting the cytokine response in COVID-19 caused by SARS-CoV-2. It is also under research for treating psoriatic arthritis (PsA) and renal antibody-mediated rejection [1] [2].

Topsalysin, a prostate-specific antigen (PSA)-activated protoxin, comprises a synthetic proaerolysin fusion protein targeting human prostate-specific antigen. This compound has demonstrated tumor-suppressive effects in a mouse model [1].

Asperglaucin A, an atypical phthalide-like derivative, exhibits potent antibacterial activities, demonstrating effectiveness against the plant pathogens Pseudomonas syringae pv actinidae (Psa) and Bacillus cereus, with a minimum inhibitory concentration (MIC) of 6.25 μM [1].

AIM-100 is a Ack1 inhibitor (IC50: 24 nM).

Asperglaucin B, an alkylated salicylaldehyde derivative isolated from the fungus Aspergillus chevalieri SQ-8, exhibits significant antibacterial properties. This compound demonstrates potent activity against the plant pathogens Pseudomonas syringae pv actinidae (Psa) and Bacillus cereus, achieving a minimum inhibitory concentration (MIC) value of 6.25 μM [1].